secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001372514-23-000154
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora's KIO-301 shows vision improvement in blind RP patients in Phase I/II trial
--------------------------------------------------------------------------------

- Visual field increased significantly (p<0.05) at days 7 and 14; high-dose group gained 0.30 logMAR (3 lines) visual acuity.
- Functional MRI showed increased brain activity in visual cortex; mobility test improvement from 24.7% to 60.0% at day 28.
- No serious adverse events or retinal inflammation; duration of effect supports monthly IVT injection.
- Company plans sham-controlled Phase II trial in 2024; will share ABACUS results with FDA in Q4 2023.
- Patients with no light perception regained ability to perceive light; Odds Ratio 2.1-4.2 for light perception improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000154/0001372514-23-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000154/kprx-20231104.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer